Daily sub-cutaneous or intraperitoneal administration of CTCE-9908 was shown to prevent the spread of cancer to distant organs on average by 61%, providing positive preclinical results for CTCE-9908 against a human prostate cancer cell line.
The study was conducted by Anti Cancer, a California based company, in coordination with the scientists at Chemokine. The results are consistent with previously disclosed experimental animal models, where CTCE-9908 reduced bone, skin and lung cancer metastases by 50-70%.
Further studies are planned to assess the cumulative benefits of CTCE-9908 in combination with the currently used anticancer chemotherapeutic agents. Recent scientific evidence supports the theory of combining CTCE-9908 with chemotherapy to overcome drug resistant cancers.
Prostate cancer is the second most common cancer in men. According to the National Cancer Institute, there are approximately 230,000 new cases of prostate cancer each year in the US with approximately 30,000 deaths occurring annually. Metastasis, (the spread of cancer to distant organs), is a common feature in many cancers, including cancer of the prostate.